SCNX
Scienture Holdings, Inc.
Price Chart
Latest Quote
$0.38
-0.01 (-1.55%)
Current Price
| Previous Close | $0.39 |
| Open | $0.41 |
| Day High | $0.43 |
| Day Low | $0.38 |
| Volume | 1,000,677 |
Stock Information
| Shares Outstanding | 40.63M |
| Total Debt | $10K |
| Cash Equivalents | $3.54M |
| Revenue | $478K |
| Net Income | $-41.85M |
| Sector | Healthcare |
| Industry | Pharmaceutical Retailers |
| Market Cap | $15.51M |
| EPS (TTM) | $-2.37 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $11.98M |
| Sales | $478K |
| Income | $-41.85M |
| Book/sh | $1.65 |
| Cash/sh | $0.09 |
| Employees | 4 |
Financial Ratios
| Quick Ratio | 1.52 |
| Current Ratio | 1.70 |
| Debt/Eq | 0.01 |
Returns & Margins
| ROA | -10.82% |
| ROE | -56.56% |
| Gross Margin | 80.53% |
| Operating Margin | -6230.80% |
Ownership
| Insider Ownership | 13.31% |
| Institutional Ownership | 3.87% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.36 |
| P/S | 32.48 |
| P/B | 0.23 |
Analyst Data
| Recommendation | buy |
| Target Price | $1.50 |
Technical Indicators
| SMA20 | $0.38 |
| SMA50 | $0.39 |
| SMA200 | $0.56 |
| RSI | 40.61 |
| ATR | 0.0389 |
| Shares Float | 32.79M |
| Short Float | 2.46% |
| Short Ratio | 2.75 |
| Rel Volume | 2.23 |
Performance History
| Week | +1.60% |
| Month | -2.05% |
| Quarter | -16.41% |
| 6 Months | -30.55% |
| YTD | -26.68% |
| Year | -60.21% |
| 3 Years | -86.81% |
| 5 Years | -99.24% |
| 10 Years | -99.28% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.38 | 1,003,300 |
| 2026-06-17 | $0.39 | 377,500 |
| 2026-06-16 | $0.38 | 339,700 |
| 2026-06-15 | $0.36 | 491,500 |
| 2026-06-12 | $0.38 | 332,000 |
| 2026-06-11 | $0.38 | 540,100 |
| 2026-06-10 | $0.35 | 203,500 |
| 2026-06-09 | $0.37 | 2,386,000 |
| 2026-06-08 | $0.35 | 273,400 |
| 2026-06-05 | $0.36 | 188,400 |
| 2026-06-04 | $0.38 | 239,600 |
| 2026-06-03 | $0.38 | 431,200 |
| 2026-06-02 | $0.39 | 588,200 |
| 2026-06-01 | $0.40 | 443,100 |
| 2026-05-29 | $0.41 | 98,000 |
| 2026-05-28 | $0.42 | 281,400 |
| 2026-05-27 | $0.39 | 177,000 |
| 2026-05-26 | $0.40 | 165,900 |
| 2026-05-22 | $0.40 | 295,400 |
| 2026-05-21 | $0.40 | 146,500 |
| 2026-05-20 | $0.39 | 396,200 |
| 2026-05-19 | $0.39 | 295,500 |
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
đ° Latest News
EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch
Benzinga âĸ 2026-06-09T11:46:07Z
BC-Most Active Stocks
Associated Press Finance âĸ 2026-03-11T14:30:34ZScienture, BlinkRx announce strategic collaboration to expand access to Arbli
TipRanks âĸ 2025-12-11T13:20:49Z
EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction
Benzinga âĸ 2025-11-13T12:50:58Z
Scienture Holdings: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-12T22:49:48ZEXCLUSIVE: Scienture Expands Access To Arbli Losartan Oral Suspension With Addition To Formularies Covering 100 Million Lives
Benzinga âĸ 2025-11-04T12:51:24Z
EXCLUSIVE: Scienture Launches Arbli Oral Suspension, Expanding Options For Hypertension Patients
Benzinga âĸ 2025-10-23T11:51:05Z
EXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions
Benzinga âĸ 2025-10-01T14:46:10Z
Scienture Secures Rebate Deal to Promote Stroke and Diabetes Drug Adoption
MT Newswires âĸ 2025-09-16T12:51:54ZEXCLUSIVE: Scienture Secures PBM-Led Rebate Agreement To Position Hypertension Drug For Rapid Adoption In US Market
Benzinga âĸ 2025-09-16T11:45:50Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $100,127 | $130,638 | $1,314,800 | $4,730,897 |
| Cost Of Revenue | $100,127 | $130,638 | $1,314,800 | $4,730,897 |
| Total Revenue | $431,609 | $136,643 | $1,363,830 | $10,250,168 |
| Operating Revenue | $431,609 | $136,643 | $1,363,830 | $10,250,168 |
| Expenses | ||||
| Interest Expense | $4,083,206 | $1,335,631 | $1,143,223 | $336,206 |
| Total Expenses | $16,676,401 | $14,837,658 | $5,760,281 | $12,290,887 |
| Other Income Expense | $-23,481,846 | $-2,877,567 | $-2,947,388 | $-47,506 |
| Other Non Operating Income Expenses | $-53,446 | - | $14,543 | - |
| Net Non Operating Interest Income Expense | $-3,780,504 | $-1,200,294 | $-1,139,025 | $-315,217 |
| Interest Expense Non Operating | $4,083,206 | $1,335,631 | $1,143,223 | $336,206 |
| Operating Expense | $16,576,274 | $14,707,020 | $4,445,481 | $7,559,990 |
| Other Operating Expenses | $97,261 | $416,311 | $100,280 | $993,185 |
| General And Administrative Expense | $14,522,743 | $12,054,019 | $4,345,201 | $6,566,805 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-41,512,264 | $-18,244,480 | $-8,482,864 | $-1,965,673 |
| Net Interest Income | $-3,780,504 | $-1,200,294 | $-1,139,025 | $-315,217 |
| Interest Income | $302,702 | $135,337 | $4,198 | $20,989 |
| Normalized Income | $-19,158,097 | $-15,448,801 | $-5,535,476 | $-1,918,167 |
| Net Income From Continuing And Discontinued Operation | $-41,512,264 | $9,065,798 | $-17,843,574 | $-3,472,099 |
| Total Operating Income As Reported | $-42,590,842 | $-14,701,015 | $-4,396,451 | $-2,915,969 |
| Net Income Common Stockholders | $-41,512,264 | $9,065,798 | $-17,843,574 | $-3,472,099 |
| Net Income | $-41,512,264 | $9,065,798 | $-17,843,574 | $-3,472,099 |
| Net Income Including Noncontrolling Interests | $-41,512,264 | $9,065,798 | $-17,843,574 | $-3,909,868 |
| Net Income Discontinuous Operations | $0 | $27,310,278 | $-9,360,710 | $-1,506,426 |
| Net Income Continuous Operations | $-41,512,264 | $-18,244,480 | $-8,482,864 | $-2,403,442 |
| Pretax Income | $-43,507,142 | $-18,778,876 | $-8,482,864 | $-2,403,442 |
| Special Income Charges | $-26,634,254 | $-2,874,968 | $-2,798,968 | $-873,050 |
| Interest Income Non Operating | $302,702 | $135,337 | $4,198 | $20,989 |
| Operating Income | $-16,244,792 | $-14,701,015 | $-4,396,451 | $-2,040,719 |
| Gross Profit | $331,482 | $6,005 | $49,030 | $5,519,271 |
| Per Share | ||||
| Diluted EPS | $-2.70 | $2.48 | $-23.35 | $-6.15 |
| Basic EPS | $-2.70 | $2.69 | $-23.35 | $-6.15 |
| Other | ||||
| Tax Effect Of Unusual Items | $-1,074,233 | $-81,888 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-15,503,755 | $-14,512,317 | $-3,342,423 | $-1,825,026 |
| Total Unusual Items | $-23,428,400 | $-2,877,567 | $-2,947,388 | $-47,506 |
| Total Unusual Items Excluding Goodwill | $-23,428,400 | $-2,877,567 | $-2,947,388 | $-47,506 |
| Reconciled Depreciation | $491,781 | $53,361 | $1,049,830 | $194,704 |
| EBITDA (Bullshit earnings) | $-38,932,155 | $-17,389,884 | $-6,289,811 | $-1,872,532 |
| EBIT | $-39,423,936 | $-17,443,245 | $-7,339,641 | $-2,067,236 |
| Diluted Average Shares | $15,347,312 | $3,653,609 | $2,381,443 | $564,863 |
| Basic Average Shares | $15,347,312 | $3,375,325 | $764,058 | $564,863 |
| Diluted NI Availto Com Stockholders | $-41,512,264 | $9,065,798 | $-17,843,574 | $-3,472,099 |
| Tax Provision | $-1,994,878 | $-534,396 | $0 | - |
| Gain On Sale Of Ppe | $0 | $-374,968 | $-2,798,968 | $2,200 |
| Gain On Sale Of Business | $-288,204 | $0 | - | - |
| Write Off | $0 | $2,500,000 | $0 | $875,250 |
| Impairment Of Capital Assets | $26,346,050 | - | $5,129,115 | $0 |
| Gain On Sale Of Security | $3,205,854 | $-2,599 | $-148,420 | $825,544 |
| Research And Development | $1,956,270 | $2,236,690 | $0 | $993,185 |
| Selling General And Administration | $14,522,743 | $12,054,019 | $4,345,201 | $6,566,805 |
| Other Gand A | $12,404,175 | $9,942,953 | $3,718,654 | $2,985,716 |
| Salaries And Wages | $2,118,568 | $2,111,066 | $626,547 | $3,581,089 |
| Minority Interests | - | - | $0 | $437,769 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-852,680 | $-18,700,839 | $542,353 | $763,136 |
| Total Assets | $84,178,330 | $104,853,805 | $12,532,913 | $3,710,026 |
| Total Non Current Assets | $76,261,924 | $98,548,328 | $9,779,850 | $1,616,903 |
| Non Current Prepaid Assets | $0 | $22,039 | $10,531 | $49,029 |
| Non Current Deferred Assets | $0 | $534,396 | - | - |
| Non Current Deferred Taxes Assets | $0 | $534,396 | - | - |
| Non Current Note Receivables | $5,000,000 | $0 | - | - |
| Non Current Accounts Receivable | $250,000 | - | - | - |
| Goodwill And Other Intangible Assets | $70,973,064 | $97,772,960 | $0 | $0 |
| Other Intangible Assets | $70,973,064 | $76,400,000 | $8,962,688 | - |
| Current Assets | $7,916,406 | $6,305,477 | $2,753,063 | $2,093,123 |
| Assets Held For Sale Current | $0 | $8,145 | $176,355 | $198,324 |
| Current Deferred Assets | $47,384 | $534,800 | $0 | - |
| Prepaid Assets | $262,278 | $4,560 | $50,724 | $104,461 |
| Inventory | $213,408 | $0 | $968 | $65,523 |
| Receivables | $731,328 | $5,449,876 | $2,524,702 | $629,921 |
| Notes Receivable | $0 | $1,300,000 | $1,300,000 | $0 |
| Accounts Receivable | $731,328 | $11,106 | $0 | $629,921 |
| Cash Cash Equivalents And Short Term Investments | $6,662,008 | $308,096 | $314 | $1,094,894 |
| Cash And Cash Equivalents | $6,662,008 | $308,096 | $314 | $1,094,894 |
| Cash Financial | $6,662,008 | $308,096 | $314 | $1,094,894 |
| Other Receivables | - | $4,138,770 | $1,224,702 | - |
| Other Non Current Assets | - | - | $9,570,603 | $450,845 |
| Allowance For Doubtful Accounts Receivable | - | - | $-32,074 | $-98,841 |
| Gross Accounts Receivable | - | - | $853,878 | $728,762 |
| Debt | ||||
| Total Debt | $24,137 | $3,532,501 | $209,504 | $1,583,907 |
| Long Term Debt And Capital Lease Obligation | $0 | $768,744 | $176,909 | $1,220,368 |
| Current Debt And Capital Lease Obligation | $24,137 | $2,763,757 | $32,595 | $363,539 |
| Net Debt | - | $3,004,602 | $6,403,092 | - |
| Long Term Debt | - | $612,275 | $25,000 | $333,333 |
| Current Debt | - | $2,700,423 | $6,530,000 | $166,667 |
| Other Current Borrowings | - | $2,700,423 | $6,530,000 | $166,667 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $14,057,946 | $25,781,684 | $11,990,560 | $3,367,159 |
| Total Non Current Liabilities Net Minority Interest | $11,322,595 | $17,874,791 | $434,205 | $1,220,368 |
| Other Non Current Liabilities | $285,000 | $1,285,000 | - | - |
| Derivative Product Liabilities | $0 | $2,296,834 | $0 | - |
| Non Current Deferred Liabilities | $11,037,595 | $13,524,213 | - | - |
| Non Current Deferred Taxes Liabilities | $11,037,595 | $13,524,213 | - | - |
| Current Liabilities | $2,735,351 | $7,906,893 | $11,556,355 | $2,146,791 |
| Other Current Liabilities | $610,914 | $930,722 | $9,900,532 | $916,521 |
| Payables And Accrued Expenses | $2,100,300 | $4,212,414 | $1,623,228 | $861,604 |
| Payables | $1,443,266 | $2,898,683 | $1,463,014 | $590,374 |
| Accounts Payable | $1,443,266 | $2,898,683 | $1,463,014 | $527,984 |
| Liabilities Heldfor Sale Non Current | - | $0 | $257,296 | - |
| Current Deferred Liabilities | - | - | $0 | $5,127 |
| Other Payable | - | - | $420,310 | $62,390 |
| Current Notes Payable | - | - | - | $166,667 |
| Equity | ||||
| Common Stock Equity | $70,120,384 | $79,072,121 | $542,353 | $763,136 |
| Total Equity Gross Minority Interest | $70,120,384 | $79,072,121 | $542,353 | $342,867 |
| Stockholders Equity | $70,120,384 | $79,072,121 | $542,353 | $763,136 |
| Retained Earnings | $-80,551,237 | $-39,038,973 | $-33,245,940 | $-19,719,536 |
| Other | ||||
| Ordinary Shares Number | $40,630,815 | $8,750,582 | $905,008 | $626,247 |
| Share Issued | $40,630,815 | $8,750,582 | $905,008 | $626,247 |
| Tangible Book Value | $-852,680 | $-18,700,839 | $542,353 | $763,136 |
| Invested Capital | $70,120,384 | $82,384,819 | $542,353 | $1,263,136 |
| Working Capital | $5,181,055 | $-1,601,416 | $-8,803,292 | $-53,668 |
| Capital Lease Obligations | $24,137 | $219,803 | $209,504 | $1,083,907 |
| Total Capitalization | $70,120,384 | $79,684,396 | $542,353 | $1,096,469 |
| Additional Paid In Capital | $150,671,215 | $118,111,007 | $33,788,284 | $20,482,666 |
| Capital Stock | $406 | $87 | $9 | $6 |
| Common Stock | $406 | $87 | $9 | $6 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $0 | $156,469 | $176,909 | $887,035 |
| Current Capital Lease Obligation | $24,137 | $63,334 | $32,595 | $196,872 |
| Current Accrued Expenses | $657,034 | $1,313,731 | $160,214 | $271,230 |
| Goodwill | $0 | $21,372,960 | $0 | - |
| Net PPE | $38,860 | $218,933 | $198,716 | $1,117,029 |
| Gross PPE | $38,860 | $218,933 | $198,716 | $1,117,029 |
| Other Properties | $38,860 | $218,933 | $198,716 | $1,117,029 |
| Finished Goods | $213,408 | $0 | $968 | $0 |
| Minority Interest | - | - | $0 | $-420,269 |
| Current Deferred Revenue | - | - | $0 | $5,127 |
| Raw Materials | - | - | $0 | $65,523 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-13,379,683 | $-14,277,238 | $-2,225,192 | $-1,564,668 |
| Operating Activities | ||||
| Operating Cash Flow | $-13,379,683 | $-14,265,238 | $-2,225,192 | $-1,564,668 |
| Cash From Discontinued Operating Activities | $2,799 | $-979,075 | $-5,870,449 | $-1,365,648 |
| Cash Flow From Continuing Operating Activities | $-13,382,482 | $-13,286,163 | $3,645,257 | $-199,020 |
| Operating Gains Losses | $-2,991,368 | $2,599 | $178,158 | $76,963 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $27,552,791 | $-275,717 | $-427,845 |
| Cash From Discontinued Investing Activities | $0 | $29,931,815 | $68,737 | $-428,594 |
| Cash Flow From Continuing Investing Activities | $0 | $-2,379,024 | $-344,454 | $749 |
| Capital Expenditure | - | $-12,000 | - | $-450,845 |
| Net Other Investing Changes | - | $-12,000 | - | - |
| Capital Expenditure Reported | - | - | $0 | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $26,293,039 | $0 | $0 | $130,918 |
| Financing Cash Flow | $19,733,595 | $-12,979,770 | $1,406,332 | $-35,171 |
| Cash From Discontinued Financing Activities | $0 | $-5,000 | $-500,000 | $-275,000 |
| Cash Flow From Continuing Financing Activities | $19,733,595 | $-12,974,770 | $1,906,332 | $239,829 |
| Net Other Financing Charges | $-400,000 | $-1,246,346 | $1,654,710 | $108,036 |
| Cash Dividends Paid | $0 | $-14,858,831 | $0 | - |
| Common Stock Dividend Paid | $0 | $-14,858,831 | $0 | - |
| Net Common Stock Issuance | $26,293,039 | $0 | $0 | $130,918 |
| Common Stock Issuance | $26,293,039 | $0 | $0 | $130,918 |
| Other | ||||
| Repayment Of Debt | $-9,775,444 | $0 | $-150,000 | $0 |
| Issuance Of Debt | $3,616,000 | $3,104,000 | $400,000 | $0 |
| Interest Paid Supplemental Data | $0 | $0 | $733,694 | $336,206 |
| End Cash Position | $6,662,008 | $308,096 | $314 | $1,094,894 |
| Beginning Cash Position | $308,096 | $314 | $1,094,891 | $3,122,578 |
| Changes In Cash | $6,353,912 | $307,782 | $-1,094,577 | $-2,027,684 |
| Proceeds From Stock Option Exercised | $0 | $26,407 | $1,622 | $875 |
| Net Issuance Payments Of Debt | $-6,159,444 | $3,104,000 | $250,000 | $0 |
| Net Long Term Debt Issuance | $-6,159,444 | $3,104,000 | $250,000 | $0 |
| Long Term Debt Payments | $-9,775,444 | $0 | $-150,000 | $0 |
| Long Term Debt Issuance | $3,616,000 | $3,104,000 | $400,000 | $0 |
| Net Investment Purchase And Sale | $0 | $-2,500,000 | $0 | - |
| Purchase Of Investment | $0 | $-2,500,000 | $0 | - |
| Net Business Purchase And Sale | $0 | $132,976 | $-344,454 | $0 |
| Sale Of Business | $0 | $132,976 | $0 | - |
| Net PPE Purchase And Sale | $0 | $-12,000 | $0 | $749 |
| Purchase Of PPE | $0 | $-12,000 | - | $0 |
| Change In Working Capital | $-3,065,331 | $-2,599,571 | $5,513,247 | $257,582 |
| Change In Other Current Liabilities | $-42,420 | $-113,977 | $-225,676 | $491,432 |
| Change In Payables And Accrued Expense | $-1,815,789 | $403,956 | $2,016,317 | $-11,861 |
| Change In Accrued Expense | $-248,574 | $-44,616 | $58,692 | $-211,694 |
| Change In Payable | $-1,567,215 | $448,572 | $1,957,625 | $199,833 |
| Change In Account Payable | $-1,567,215 | $448,572 | $1,607,625 | $199,833 |
| Change In Prepaid Assets | $-193,023 | $34,656 | $38,367 | $335,066 |
| Change In Inventory | $-213,408 | $968 | $4,232,947 | $-51,737 |
| Change In Receivables | $-800,691 | $-2,925,174 | $-548,708 | $-505,318 |
| Changes In Account Receivables | $-720,222 | $-11,106 | $-293,784 | $369,932 |
| Other Non Cash Items | $7,274,636 | $5,510,740 | $257,771 | $254,106 |
| Stock Based Compensation | $2,068,892 | $25,584 | $257,772 | $254,106 |
| Asset Impairment Charge | $26,346,050 | $2,500,000 | $5,129,115 | $1,421,067 |
| Depreciation Amortization Depletion | $491,781 | $53,361 | $1,049,830 | $194,704 |
| Depreciation And Amortization | $491,781 | $53,361 | $1,049,830 | $194,704 |
| Amortization Cash Flow | $453,846 | $0 | $814,790 | $0 |
| Amortization Of Intangibles | $453,846 | $0 | $814,790 | $0 |
| Depreciation | $37,935 | $53,361 | $235,040 | $194,704 |
| Gain Loss On Investment Securities | $-3,205,854 | $2,599 | $178,158 | $79,163 |
| Gain Loss On Sale Of Business | $214,486 | $0 | - | - |
| Net Income From Continuing Operations | $-43,507,142 | $-18,778,876 | $-8,482,864 | $-2,403,442 |
| Income Tax Paid Supplemental Data | - | $0 | $0 | $0 |
| Purchase Of Business | - | $0 | $-344,454 | $0 |
| Sale Of PPE | - | - | $0 | $749 |
| Change In Other Current Assets | - | - | $306,527 | $0 |
| Net Short Term Debt Issuance | - | - | - | - |
| Short Term Debt Payments | - | - | - | - |
| Change In Other Working Capital | - | - | - | - |
Fetched: 2026-06-20